Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IVIg in Inflammatory Myopathies
NCT00001261Phase 2Completed
- Sponsor
- National Institute of Neurological Disorders and Stroke
- Start
- May 1990
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of immune globulin in polymyositis (PM), dermatomyositis (DM) and inclusion body myositis (IBM) (2 arms), sponsored by National Institute of Neurological Disorders and Stroke. Primary endpoint: Change in Muscle Strength at 6 months. Started May 1990; status: completed.
02
Drugs
immune globulin
03
Conditions
polymyositis (PM)dermatomyositis (DM)inclusion body myositis (IBM)
Beyond the preview
Go deeper on NCT00001261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00001261.